Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
Κύριοι συγγραφείς: | Chapman, K, Pavord, I, Paggiaro, P, Sciurba, F, Bafadhel, M, Bradford, E, Harris, S, Mayer, B, Rubin, D, Yancey, S |
---|---|
Μορφή: | Conference item |
Έκδοση: |
American Thoracic Society
2018
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Exacerbation Endpoints
ανά: Bafadhel, M, κ.ά.
Έκδοση: (2018) -
Mepolizumab for eosinophilic COPD
ανά: Sciurba, F, κ.ά.
Έκδοση: (2018) -
Mepolizumab for eosinophilic chronic obstructive pulmonary disease
ανά: Pavord, I, κ.ά.
Έκδοση: (2017) -
Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
ανά: Pavord, I, κ.ά.
Έκδοση: (2017) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
ανά: Gunsoy, N, κ.ά.
Έκδοση: (2017)